Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment
Study sponsor: Amylyx Pharmaceuticals Inc. · AMLX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-01-19Actual
Enrollment · participants664Actual
Source updated2024-08-14Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.